Clinical Trial Update: CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for CNP-103 in adolescents and adults (ages 12-35) recently diagnosed with Type 1 Diabetes, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• CNP-103

Snippet

Sponsor: COUR Pharmaceutical Development Company, Inc. | Conditions: Type 1 Diabetes Mellitus, T1D | Phase 1, Phase 2 | Status: RECRUITING